Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

bioAffinity Technologies, Inc. Regulatory Filings 2026

Apr 7, 2026

35439_rns_2026-04-07_b196cbf0-94ec-465e-95a9-c0113d223a62.zip

Regulatory Filings

Open in viewer

Opens in your device viewer

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 7, 2026

bioAffinity Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware 001-41463 46-5211056
(State
or other jurisdiction of
incorporation) (Commission File
Number) (I.R.S.
Employer Identification
Number)

3300 Nacogdoches Road , Suite 216

San Antonio , Texas 78217

(Address of principal executive offices, including zip code)

(210) 698-5334

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| --- | --- |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

| Title
of each class | Trading
Symbols | Name
of each exchange on which registered |
| --- | --- | --- |
| Common
Stock, par value $0.007 per share | BIAF | The
Nasdaq Stock Market LLC (Nasdaq
Capital Market) |
| Warrants
to purchase Common Stock | BIAFW | The
Nasdaq Stock Market LLC (Nasdaq
Capital Market) |

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Item 8.01. Other Events.

On April 7, 2026, bioAffinity Technologies, Inc., a Delaware corporation, issued a press release announcing that its CyPath ® Lung test will be featured a the invitation-only “Advances in Early Lung Cancer Detection” symposium at the Cleveland Clinic in Cleveland, Ohio, on April 16, 2026.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number Description
99.1 Press Release issued by bioAffinity Technologies, Inc., dated April 7, 2026
104 Cover
Page Interactive Data File (embedded within the XBRL document)

Field: Page; Sequence: 2; Options: NewSection; Value: 2

  • 2 -

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

| Date:
April 7, 2026 | |
| --- | --- |
| By: | /s/
Maria Zannes |
| Name: | Maria
Zannes |
| Title: | President
and Chief Executive Officer |

Field: Page; Sequence: 3; Options: Last

  • 3 -

Field: /Page

Field: Set; Name: xdx; ID: xdx_08B_extensions eJx1kcFuwjAMhp+Ad7CqHRGk1cam3raKoWkwVYDYrl4xI6KNKydl8Eh7y6UpCA5bFClO/H/+bSWK+tGEn3VJAh9P8yksqapLdARz2pCQKcgrspfXFPw5py9tnaBx4XoGM/YMeWY0uEP/HpR7bWmdgrodqtEwGfkgVQ+Qz6Jem8/YbPSajNNYApo15MK1aHIox67CEg9suDoGpxWJ1WxSiAeqS/9AouIE3niP3yw7C9NpFvX6YfWiiXBTe9X44Mi0JIxLqryd7ejLDt0UjXVcpe8o7Wx2yXkjxRYt+ckqNgvHxW5G1SeJF8cqSWL1eOrjzIBjqE8UdBgE7g+fq6o5ygrLhtRAqfucZLFFoX+srqv2oUaBfYvCTYCh9j9hW/zs+AvMII7O